TG Therapeutics, Inc. (NKB2)
Market Closed
3 Jun, 20:00
XFRA 
€
34. 80
+3
+9.43%
€
5.17B Market Cap
- P/E Ratio
- Div Yield
450 Volume
0.03 Eps
€ 31.8
Previous Close Want to track NKB2 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
TG Therapeutics, Inc. (NKB2) Statistics
Valuation metrics
Market Cap 5.17B
Enterprise value 4.32B
Trailing P/E (ttm) 13.74
Forward P/E -14.76
PEG ratio 0.04
Price/Sales (ttm) 7.39
Price/Book (mrq) 9.55
Enterprise Value/Revenue 7.18
Enterprise Value/EBITDA 33.62
Overview
Shares outstanding 153.09M
Float 135.1M
Shares short -
% Held by insiders 0.07%
% Held by institutions 0.7%
Average volume (10 days) 113
Average volume (90 days) 844
Price summary
52-Week low 22.46
52-Week high 36.4
Beta 1.68
50-Day moving average 29.6
200-Day moving average 27.35
Dividends and splits
Forward annual dividend rate -
Forward annual dividend yield -
Trailing annual dividend rate -
Trailing annual dividend yield -
5-Year annual dividend yield -
Payout ratio -
Dividend Date -
Ex-Dividend Date -
Last split factor 100:5,625
Last split Date 30 Apr 2012
Financials
Fiscal year
Fiscal year ends 31 Dec 2025
Most recent quarter (mrq) 31 Mar 2026
Profitability
Profit margin 0.66%
Operating margin 0.17%
Operational effectiveness
Return on assets 0.09%
Return on equity 1.13%
Income Statement
Revenue (ttm) 602.01M
Revenue per share (ttm) 4.87
Quarterly revenue growth (yoy) 0.7%
Gross profit (ttm) 499.99M
EBITDA 159.34M
Net income to common (ttm) 397.04M
Diluted EPS (ttm) 2.46
Quarterly earnings growth (yoy) 2.91%
Balance Sheet
Total cash (mrq) 442.2M
Total cash per share (mrq) 3.63
Total debt (mrq) 647.75M
Total Debt/Equity (mrq) 129.23
Current ratio (mrq) 5.81%
Book value per share (mrq) 3.54
Cash Flow
Cash flow statement -11.99M
Levered free cash flow (LFCF) -25.93M
